TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07876856: A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 1/2 Study to Evaluate AHB-137 Injection Followed by TVAX-008 Injection in Participants With HBeAg-Negative Chronic Hepatitis B Treated With Nucleos(t)Ide

Sponsor: Ausper Biopharma Co., Ltd. · Phase: PHASE1/PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 105 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,996,800

Rescue Site Savings

+$5,272,890

Unlock Full NCT07876856 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07876856 Rescue Dossier →